Results 101 to 110 of about 52,048 (217)

Risk factors for pneumonia in patients with schizophrenia

open access: yesNeuropsychopharmacology Reports, 2018
Aim Pneumonia is a major cause of death in patients with schizophrenia. Preventive strategies based on identifying the risk factors are needed to reduce pneumonia‐related mortality.
Takahiro Haga   +5 more
doaj   +1 more source

Subchronic Exposure to Aripiprazole Subtly Impacts on Rodents' Sperm Quality and Fertility

open access: yesBasic &Clinical Pharmacology &Toxicology, Volume 138, Issue 3, March 2026.
ABSTRACT Aripiprazole, a third‐generation antidepressant/antipsychotic drug, acts on serotonergic and dopaminergic receptors and is widely prescribed for mental disorders, such as depression and schizophrenia. Studies indicate that this class of drugs can impact directly on sperm quality and fertility.
Maria Joana Nogueira de Moura   +7 more
wiley   +1 more source

Assessment of a method to detect signals for updating systematic reviews. [PDF]

open access: yes, 2014
BackgroundSystematic reviews are a cornerstone of evidence-based medicine but are useful only if up-to-date. Methods for detecting signals of when a systematic review needs updating have face validity, but no proposed method has had an assessment of ...
Johnsen, Breanne   +3 more
core   +1 more source

Urinary tract infection‐related delirium in Alzheimer's disease and related dementias: Clinical challenges and translational opportunities

open access: yesAlzheimer's &Dementia, Volume 22, Issue 2, February 2026.
Abstract Alzheimer's disease and related dementias (ADRD) affects millions of patients worldwide and is a leading cause of morbidity in older adults. Patients with ADRD are particularly susceptible to developing urinary tract infection (UTI) and UTI‐related delirium, creating a self‐perpetuating cycle in which ADRD increases vulnerability to infection ...
Sarah Kim   +3 more
wiley   +1 more source

Efficacy and safety of atypical antipsychotic drugs (quetiapine, risperidone, aripiprazole and paliperidone) compared with placebo or typical antipsychotic drugs for treating refractory schizophrenia: overview of systematic reviews

open access: yesSão Paulo Medical Journal
CONTEXT AND OBJECTIVE: According to some cohort studies, the prevalence of refractory schizophrenia (RS) is 20-40%. Our aim was to evaluate the effectiveness and safety of aripiprazole, paliperidone, quetiapine and risperidone for treating RS.
Tamara Melnik   +3 more
doaj   +1 more source

Differential Effects of Various Typical and Atypical Antipsychotics on Plasma Glucose and Insulin Levels in the Mouse: Evidence for the Involvement of Sympathetic Regulation [PDF]

open access: bronze, 2008
Yvette E. Savoy   +8 more
openalex   +1 more source

Differential Effectiveness of Atypical Antipsychotics on Hallucinations

open access: hybrid, 2021
Igne Sinkeviciute   +11 more
openalex   +1 more source

Antipsychotic switching in bipolar disorders: a systematic review. [PDF]

open access: yes, 2017
With the increasingly widespread use of antipsychotics in bipolar disorder (BD), switching among these agents and between antipsychotics and mood stabilizers has become more common, in particular, since the introduction of the novel atypical ...
Bernardo Arroyo, Miquel   +5 more
core   +1 more source

Machine learning methods for predicting adverse drug events: A systematic review

open access: yesBritish Journal of Clinical Pharmacology, Volume 92, Issue 2, Page 422-444, February 2026.
Abstract Predicting adverse drug events (ADEs) in outpatient settings is crucial for improving medication safety, identifying high‐risk patients and reducing health‐care costs. While traditional methods struggle with the complexity of health‐care data, machine learning (ML) models offer improved prediction capabilities; however, their effectiveness in ...
Niaz Chalabianloo   +8 more
wiley   +1 more source

The use of atypical antipsychotics in the management of schizophrenia [PDF]

open access: bronze, 1999
Narelle Campbell   +4 more
openalex   +1 more source

Home - About - Disclaimer - Privacy